Chronic News and Research

RSS

Obesity drug tirzepatide reduces bodyweight, waist circumference regardless of the duration of disease

New research to be presented at this year's European Congress on Obesity (Venice, Italy, May 12-15) shows that the obesity medication tirzepatide consistently reduces bodyweight and waist circumference regardless of the length of time the person has been living with overweight or obesity.

13 Mar 2024

UArizona study identifies link between poor sleep and migraine attacks

A new study by researchers at the University of Arizona Health Sciences identified a link between poor sleep and migraine attacks that suggests improving sleep health may diminish migraine attacks in people with migraine.

13 Mar 2024

Gonorrhea cases spike among young women in Europe, new study reveals

Gonorrhea cases have surged among young women in 15 European countries in 2022 and 2023, with a less significant increase observed among young men, highlighting shifts in sexual behaviors and potential changes in the transmissibility of Neisseria gonorrhoeae

13 Mar 2024

Scientists uncover an overlooked mechanism in the gut immune system of Crohn's disease patients

A team of scientists from DTU and other European universities have uncovered an overlooked mechanism in the gut immune system of patients suffering from severe cases of Crohn's disease.

13 Mar 2024

Age-related changes in the shape of brain neurons lead to middle-age obesity

Nagoya University researchers and their colleagues in Japan have found that middle-age obesity is caused by age-related changes in the shape of neurons in the hypothalamus, a region of the brain that controls metabolism and appetite.

13 Mar 2024

LGM Pharma unveils enhanced analytical testing services and expands CDMO portfolio with additional suppository manufacturing capabilities

LGM Pharma, a leading provider of tailored API and CDMO services for the full drug product lifecycle, today announced a significant enhancement of its capabilities: a 50% expansion and an investment exceeding $2 million in its standalone offering for Analytical Testing Services (ATS) alongside the introduction of new suppository manufacturing capabilities to its contract development and manufacturing (CDMO) portfolio.

From LGM Pharma 13 Mar 2024